Literature DB >> 25711280

First CDK 4/6 Inhibitor Heads to Market.

.   

Abstract

The FDA granted accelerated approval to palbociclib for the treatment of estrogen receptor-positive, HER2-negative metastatic breast cancer in postmenopausal women who have not yet received endocrine-based therapy. Palbociclib is the first cell cycle-targeting CDK 4/6 inhibitor to reach the market. ©2015 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25711280     DOI： 10.1158/2159-8290.CD-NB2015-028

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  3 in total

1.  Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4/6 and OCT2 functions.

Authors:  Navjotsingh Pabla; Alice A Gibson; Mike Buege; Su Sien Ong; Lie Li; Shuiying Hu; Guoqing Du; Jason A Sprowl; Aksana Vasilyeva; Laura J Janke; Eberhard Schlatter; Taosheng Chen; Giuliano Ciarimboli; Alex Sparreboom
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-06       Impact factor: 11.205

Review 2.  Osteosarcoma: prognosis plateau warrants retinoblastoma pathway targeted therapy.

Authors:  Sarah E Ballatori; Philip W Hinds
Journal:  Signal Transduct Target Ther       Date:  2016-03-25

3.  Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11.

Authors:  Yunfei Liao; Slim Sassi; Stefan Halvorsen; Yong Feng; Jacson Shen; Yan Gao; Gregory Cote; Edwin Choy; David Harmon; Henry Mankin; Francis Hornicek; Zhenfeng Duan
Journal:  Sci Rep       Date:  2017-03-06       Impact factor: 4.379
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.